Navigation Links
Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)
Date:5/17/2012

RARITAN, N.J., May 17, 2012 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA® ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy (DPN). Results of the study were presented at the 31st Annual Scientific Meeting of the American Pain Society being held May 16-19 in Honolulu, Hawaii.

Diabetes affects nearly 26 million people in the United States(1)– and its prevalence is expected to grow significantly during the coming decades(2). Over time, people with diabetes can develop a type of nerve damage called neuropathy. Approximately 60 to 70 percent of people with diabetes have some form of neuropathy(3). The most common type is diabetic peripheral neuropathy, which causes pain or loss of feeling in the toes, feet, legs, hands, and arms.

The study found, among patients who had at least a one-point reduction in pain intensity during three weeks of treatment with tapentadol ER, those who continued on an optimized dose of tapentadol ER (100-250 mg twice daily) for an additional 12 weeks experienced significantly better pain control compared to those who switched to placebo(4). Treatment-emergent adverse events reported in 10 percent or more of tapentadol ER-treated patients during the double-blind maintenance period included nausea (21.1 percent) and vomiting (12.7 percent)(4).

"Painful DPN is a common and burdensome complication of diabetes, and controlling pain in people with DPN can be challenging," said Aaron I. Vinik, M.D., Ph.D., FCP, MACP, Director of Research and Neuroendocrine Unit at Strelitz Diabetes Center for Endocrine and Metabolic Disorders at Eastern Virginia Medical School, and lead investigator of the study. "These data suggest tapentadol ER provides a significant reduction in chronic pain in adult
'/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
2. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
3. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
4. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
5. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
6. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
7. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
10. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
11. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013  Regulatory and marketplace changes have pushed ... priority list. Forward-thinking companies across ... strong Medical Affairs function is essential ... market education , and regulatory compliance. These areas ... between an organization and one of the most ...
(Date:5/24/2013)... , May 24, 2013  BD (Becton, Dickinson and Company) ... company, announced today that it will present at the Deutsche ... May 30, 2013, at 10:40 a.m. (ET). ... the BD corporate website at www.bd.com/investors and will ... About BD BD is a leading ...
(Date:5/24/2013)... , May 24, 2013 /PRNewswire-iReach/ -- Phoenix Houses ... non-profit substance abuse services organization, is hosting its tenth ... Hills Hotel on June 6, 2013.  More than 300 ... funds for the adolescent residential treatment centers, family therapy, ... honor individuals whose accomplishments have positive influences on the ...
Breaking Medicine Technology:Building Medical Affairs Capabilities to Ensure Organizational Success across Key Operational Areas 2Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 2Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 3
... Inc., a pharmaceutical company developing orally-available antiviral therapeutics to ... President and Chief Executive Officer, will present at the ... March 8, 2011, 1:30 pm ET, at the Boston ... Company Health Care Conference is a conference for institutional ...
... Advanstar Communications, Inc., a leading worldwide ... Life Sciences and Powersports industries, announced today that it ... position of Executive Vice President, Pharmaceutical/Science. With ... Chief Administrative Officer roles, this new position is another ...
Cached Medicine Technology:Chimerix to Present at Cowen and Company 31st Annual Health Care Conference 2Chimerix to Present at Cowen and Company 31st Annual Health Care Conference 3Veteran Executive Ron Wall Joins Advanstar Communications as Executive Vice President, Pharmaceutical/Science 2
(Date:5/24/2013)... Atlanta, GA (PRWEB) May 24, 2013 Started ... convention held in Orlando. 2013 marks AMTC’s 31st anniversary. ... same family, starting with supermodel Millie Lewis and her daughter, ... by top agents, managers, casting directors, and music professionals including ... Dramatic Arts and XP Media. They are kings of Hollywood ...
(Date:5/24/2013)... May 24, 2013 Amirsys today announces ... new enhancements for instructors and students. Instructors can use ... through personalize learning plan templates, targeted reading assignments, and ... 500 new assessment questions, 5,000 searchable anatomy glossary terms, ... AnatomyOne 2.0 is the first gross anatomy ...
(Date:5/24/2013)... New York, NY (PRWEB) May 24, 2013 ... of Yahoo Commerce VP, Brandon Huff as Executive Vice ... ran its commerce business units, which represented a large ... will lead digital growth as Dwell develops a fully-integrated ... him a decade of experience monetizing digital content for ...
(Date:5/24/2013)... 24 (HealthDay News) -- Low-income, minority parents have ... and are more open to vaccinating their daughters ... small new study contends. Conversely, white, middle-class ... for their daughters, according to researchers from the ... Americans will get an HPV-related cancer each year, ...
(Date:5/24/2013)... Bethesda, MD (PRWEB) May 24, 2013 ... to its growing base of clients. As a result ... reports a presence in 20 states around the ... providing medical transcription services to the healthcare industry ... nurses who use their years of clinical work ...
Breaking Medicine News(10 mins):Health News:AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013 2Health News:Amirsys AnatomyOne 2.0 Delivers Personalized Learning Plans 2Health News:Yahoo Commerce Head Joins Leadership at Dwell Media 2Health News:Low-Income, Minority Parents More Open to HPV Vaccine for Girls, Study Says 2Health News:The Dictation Source Signs Two National Hospital Chains 2Health News:The Dictation Source Signs Two National Hospital Chains 3
... CoLucid Pharmaceuticals, Inc., an,innovative biotechnology company ... announced it closed a $25 million Series ... round, which included previous investors,Pappas Ventures, Domain ... Ventures. The financing will be used to ...
... subjective decision-making , ... Los Angeles (PRWEB) July 1, ... their patients who have a heart abnormality called myocardial bridging and ... Cedars-Sinai Medical Center, the University of Texas Medical Branch and RWTH ...
... and the first day of summer is upon us, the cancer care ... the sun when spending time outdoors. Although the most prevalent cancer in ... majority of the more than 1 million annual U.S. cases of skin ... ...
... have developed a series of tests that for the first ... smell (olfactory function) in young children, according to a new ... Head and Neck Surgery . , The study, authored ... can identify a majority of 16 different test odorants that ...
... Center, Atlanta, Georgia, "Elimination of Health ... Professionals", WASHINGTON, July 1 The ... Association:, WHAT: The nation,s largest and ... minority and underserved populations, the National,Medical Association ...
... TITUSVILLE, N.J., June 30 Janssen, Division,of Ortho-McNeil-Janssen ... generic version of RISPERDAL(R) (risperidone),through Patriot Pharmaceuticals, L.L.C., ... companies are a part of the,Johnson & Johnson ... it will continue to make available branded,RISPERDAL, which ...
Cached Medicine News:Health News:CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound 2Health News:CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound 3Health News:CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound 4Health News:New System Devised To Guide Doctors Treating Patients With Symptomatic Myocardial Bridging 2Health News:New System Devised To Guide Doctors Treating Patients With Symptomatic Myocardial Bridging 3Health News:New System Devised To Guide Doctors Treating Patients With Symptomatic Myocardial Bridging 4Health News:Texas Oncology Urges Texans to ‘Save Your Skin:' Outsmart the Sun and Prevent Skin Cancer 2Health News:Texas Oncology Urges Texans to ‘Save Your Skin:' Outsmart the Sun and Prevent Skin Cancer 3Health News:Texas Oncology Urges Texans to ‘Save Your Skin:' Outsmart the Sun and Prevent Skin Cancer 4Health News:National Medical Association Hosts the 2008 Annual Convention and Scientific Assembly 2Health News:Janssen Announces Launch of Authorized Generic for RISPERDAL(R) 2Health News:Janssen Announces Launch of Authorized Generic for RISPERDAL(R) 3Health News:Janssen Announces Launch of Authorized Generic for RISPERDAL(R) 4
... Record organizes communication and chart information ... practitioners. It also manages orders, procedures, ... that traditionally rely on many people ... With Microsoft Outlook integration, HealthMatics EMR ...
... Description PANALOK is a fully-absorbable soft ... (polylactic acid) material and provides fixation ... The X-ray transparent anchor retains strength ... and eventually absorbs leaving no permanent ...
... The Bio-Anchor implant is molded from Poly ... absorption rate to insure secure fixation throughout ... eliminates implant removal complications because it is ... be over-drilled. The ribbed, press-fit anchor ...
... just got better. How can one of ... Simply by becoming more convenient to use ... arthroscopic. The TwinFix Suture Anchor with Needles ... unique, convenient and timesaving anchor inserter and ...
Medicine Products: